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The extracellular matrix (ECM) is a critical tissue component, providing structural support as well
as important regulatory signaling cues to govern cellular growth, metabolism, and differentiation.
The study of ECM proteins, however, is hampered by the low solubility of ECM components in
common solubilizing reagents. ECM proteins are often not detected during proteomics analyses
using unbiased approaches due to solubility issues and relatively low abundance compared to
highly abundant cytoplasmic and mitochondrial proteins. Decellularization has become a common
technique for ECM protein-enrichment and is frequently used in engineering studies. Solubilizing
the ECM after decellularization for further proteomic examination has not been previously
explored in depth. In this study, we describe testing of a series of protocols that enabled us to
develop a novel optimized strategy for the enrichment and solubilization of ECM components.
Following tissue decellularization, we use acid extraction and enzymatic deglycosylation to
facilitate resolubilization. The end result is the generation of three fractions for each sample:
soluble components, cellular components, and an insoluble ECM fraction. These fractions,
developed in mass spectrometry-compatible buffers, are amenable to proteomics analysis. The
developed protocol allows identification (by mass spectrometry) and quantification (by mass
spectrometry or immunoblotting) of ECM components in tissue samples.
Biological significance—The study of extracellular matrix (ECM) proteins in pathological and
non-pathological conditions is often hampered by the low solubility of ECM components in
common solubilizing reagents. Additionally, ECM proteins are often not detected during global
proteomic analyses due to their relatively low abundance compared to highly abundant
cytoplasmic and mitochondrial proteins. In this manuscript we describe testing of a series of
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protocols that enabled us to develop a final novel optimized strategy for the enrichment and
solubilization of ECM components. The end result is the generation of three fractions for each
sample: soluble components, cellular components, and an insoluble ECM fraction. By analysis of
each independent fraction, differences in protein levels can be detected that in normal conditions
would be masked. These fractions are amenable to mass spectrometry analysis to identify and
quantify ECM components in tissue samples. The manuscript places a strong emphasis on the
immediate practical relevance of the method, particularly when using mass spectrometry
approaches; additionally, the optimized method was validated and compared to other
methodologies described in the literature.
Keywords
Extracellular matrix; Enrichment; Decellularization; Heart; Solubility; Matrix metalloproteinases

1. Introduction
The extracellular matrix (ECM) is a structural scaffold for cell adhesion and migration, as
well as a signaling trigger for ECM receptors to regulate cell growth, metabolism, and
differentiation [1,2]. Therefore, a complete understanding of cell biology requires an
understanding of ECM biology. One particularly dynamic tissue remodeling process in
which ECM becomes critically important is wound repair.

NIH-PA Author Manuscript

Studying the ECM, however, is not trivial. ECM components are organized into a complex
fibrillar, three-dimensional matrix that cannot easily be solubilized or dissociated into
component units. The interlocking mesh of collagens, elastic fibers, proteoglycans, and
adhesive glycoproteins contains protein aggregates, cross-linked proteins, and glycosylated
or other post-translationally modified proteins that make solubilizing the ECM particularly
difficult [3,4]. The unusual physical properties of the ECM create challenges for
characterization using standard tissue homogenization approaches because the insoluble
components of ECM associate with fractions that are often discarded during sample
preparation. Furthermore, the presence of highly abundant cytoplasmic and mitochondrial
proteins can hamper detection of the relatively scarce ECM proteins. This is particularly a
concern for tissues with high metabolical activity, such as the heart, in which there is an
exceptionally high mitochondrial content.

NIH-PA Author Manuscript

Adverse remodeling of the left ventricle (LV) following myocardial infarction (MI) is a
leading cause of congestive heart failure and cardiovascular morbidity and mortality. PostMI, LV remodeling involves the removal of necrotic tissue and the formation of a
myocardial scar. ECM turnover is a key component of LV remodeling. A proper balance is
needed between synthesis and degradation of ECM in order to re-establish homeostasis for
adequate scar formation. The replacement of the necrotic cells with an ECM scar increases
myocardial stiffness and consequently leads to LV dysfunction [5,6]. Understanding the
changes that occur in the ECM post-MI is, therefore, pivotal for identifying factors that tip
the balance between favorable repair and adverse remodeling that can progress to heart
failure. The functional properties of the complex ECM cannot be determined without
studying the individual constituents and their individual functions.
In this manuscript, we describe the evaluation of several methodologies for the enrichment
of cardiac ECM proteins to facilitate analysis by mass spectrometry (Fig. 1). In order to
focus on the ECM components, we first analyzed proteins in the LV infarct area of wild type
(WT) mice for comparison to the LV proteins in matrix metalloproteinase (MMP)-9 null
mice at 7 days post-MI (Fig. 1, strategy 1). The 7 day time point was chosen because the
infarct is approximately 30% scar by volume at this time, which provided a natural
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overabundance of ECM protein [7]. Proteins were analyzed by mass spectrometry (MS) and
several ECM proteins were detected [8]. However, there was still a large number of cellular
proteins (cytoplasmic and mitochondrial) in the preparation, which hampered relative
quantification of the ECM components. To overcome this issue, we designed and tested a
series of protocols for the enrichment and solubilization of ECM components. The final
protocol uses a novel differential solubility-based, protein fractionation strategy that has
been optimized for the analysis of cardiac ECM by eliminating the cellular proteins present
in the LV and increasing ECM solubility.

2. Results
Using a step-wise protocol, we overcame several common issues in studying ECM proteins.
Our two objectives were: 1) to reduce the presence of cellular proteins, thereby enriching for
lower abundance ECM proteins; and 2) to efficiently solubilize and deglycosylate ECM
proteins to facilitate their analysis by proteomic approaches.
2.1. ECM enrichment by tissue decellularization

NIH-PA Author Manuscript

Intact LV samples were used to develop a method for the extraction of proteins present in
the extracellular environment, including ECM proteins and proteins attached to the ECM.
This method consisted of two steps: tissue decellularization to remove cellular proteins (Fig.
2a), and tissue homogenization with a protein extraction reagent. Tissue decellularization
protocols have been in use since the early 1970s [9]. Ott and colleagues used multiple
detergents to decellularize hearts by perfusion, including 1% polyethylene glycol (PEG), 1%
sodium dodecyl sulfate (SDS), and 1% Triton X-100 [10]. SDS was the only one of those
detergents that was able to fully decellularize the tissue. Ionic detergents, such as SDS, are
regularly used for effective solubilization of membrane proteins in order to remove cellular
components from tissues [11–13].
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In our search for an optimized decellularization/ECM enrichment strategy, we explored a
modification of the protocol described by Ott et al. [14]. Five decellularization buffers were
tested (strategy 2). Buffer # 1 was 1% SDS; buffer # 2 was 1% SDS, 20 mM NH4OH; buffer
# 3 was 1% Triton X-100, 20 mM NH4OH; buffer # 4 was 1% SDS, 1% Triton X-100; and
buffer # 5 was 1% SDS, 1% Triton X-100, 20 mM NH4OH. In contrast to Ott and
colleagues, we were not interested in keeping the intact heart as a scaffold. Therefore, the
LV was cut into small pieces before decellularization. This substantially increased the tissue
contact surface area resulting in faster decellularization (72 h versus 124 h). In addition, we
included protease inhibitors (PI) in all of the decellularization buffers. This is an essential
step to prevent proteolysis of ECM proteins by MMPs and other proteases. Only buffers that
contained SDS as the only detergent completely decellularized the tissues (buffer # 1 and
buffer # 2). Compared to other detergents, SDS has been shown to be more effective for
removal of nuclear and cytoplasmic proteins [15]. SDS affords the dual advantage of
efficiently extracting proteins and enhancing protein solubility. The denaturant properties of
SDS are due to hydrophobic interactions between proteins and the long, flexible 12-carbon
hydrocarbon tail that interacts with the hydrophobic regions of polypeptide chains, thereby
interfering with intraprotein interactions. Moreover, the polar carboxylate head group of
SDS associates with positively-charged side chains, thus disrupting ionic protein–protein
interactions [16].
In order to extract protein from the decellularized tissue, two approaches using Protein
Extraction Reagent 4 (Sigma Aldrich) were evaluated. This reagent contains thiourea (2 M)
as a chaotrope in addition to urea (7 M) and the zwitterionic detergent, C7BzO, and has been
shown to increase protein extraction and solubility compared to other detergents [17]. The
methods tested included: 1) homogenization in a lysis buffer (0.25 M sucrose, 1 mM EDTA
J Proteomics. Author manuscript; available in PMC 2014 June 28.
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in 50 mM Tris with 1× PI) for isolation of soluble components, followed by centrifugation,
and homogenization of the pellet (insoluble components) in Protein Extraction Reagent 4
with 1× PI (strategy 3); 2) direct homogenization in Protein Extraction Reagent 4 with 1× PI
(strategy 4).

NIH-PA Author Manuscript

Although the use of SDS for decellularization efficiently removed cellular proteins, there
were issues with the subsequent homogenization of the decellularized tissue. Visualization
by 1-D SDS-PAGE indicated that although the protein profiles of replicate samples were
consistent, there were aggregated proteins trapped in the wells of the gel (Fig. 2b).
Immunoblot analysis of the soluble and insoluble components (tissue solubilization, strategy
3) was conducted to assess the degree of enrichment of ECM proteins, reduction of cellular
proteins, and efficacy of the decellularization buffers. Fibronectin was chosen as the ECM
protein target, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and manganese
superoxide dismutase (MnSOD) as the cellular proteins. The decellularization buffer
collected after the first day of incubation (cellular extract) was included as a negative
control. Fibronectin was found to be enriched in the insoluble fraction of decellularized LV
treated with buffers # 1 and # 2 compared to untreated LV (Fig. 2c, lanes 4 to 6). The
cellular extract showed a low level of fibronectin present in that fraction (Fig. 2c lane 7),
indicating that a very small amount of fibronectin was lost during the ECM enrichment
process. The immunoblots for the cellular proteins showed significantly reduced levels of
MnSOD and GAPDH both in the soluble and insoluble fractions of decellularized LV
compared to the untreated (cellular) LV. Since MnSOD and GAPDH were not completely
removed, the term ECM-enriched is used instead of ECM-purified to describe the resulting
protein solution. Detection of strong immunoblot signals for MnSOD and GAPDH in the
cellular extract (Fig. 2c lane 7) provided convincing evidence for the effective removal of
cellular proteins by this treatment, supporting the idea that cellular proteins were removed
during the ECM enrichment process. Since there were lower levels of cellular proteins
remaining in the LV after decellularization with buffer # 1, compared to buffer # 2, we
chose to use buffer # 1 for the tissue decellularization step in all further experiments.
Additionally, fibronectin was mostly present only in the insoluble fraction; therefore, we
elected to use only Protein Extraction Reagent 4 (strategy 4) for tissue homogenization.
The LV decellularization protocol described above was able to effectively reduce the levels
of cellular proteins and permitted detection of less abundant ECM proteins (monitored by
fibronectin). However, complete protein solubilization was not achieved as evidenced by the
residual material that was trapped in the wells of the gels. Additionally, there was
inconsistency in the quantities of protein recovered from replicate samples, indicating a need
to enhance the reproducibility of the solubilization step.

NIH-PA Author Manuscript

2.2. High molecular weight filtration, reduction and alkylation
Protein extracts processed by the SDS decellularization method using buffer # 1 followed by
solubilization according to the method developed in strategy 4 were separated by 1-D SDSPAGE. The proteins were digested in situ with trypsin and analyzed by HPLC–electrospray
ionization–tandem mass spectrometry (HPLC–ESI–MS/MS). More than 150 proteins were
identified, including titin. Titin is the largest known protein, with a molecular weight of
3906 kDa. It seemed likely that one of the proteins trapped in the 1-D gel wells was titin.
Two methods were devised to eliminate this problem: proteins were reduced and alkylated
prior to SDS-PAGE (strategy 5); and ultra-high molecular weight proteins were removed
with a filtration device (strategy 6). Although reduction/alkylation appeared to improve
sample solubility, the protein preparation that ensued was of lower quality with smeared and
diffused protein bands (Fig. 3). When a 300 kDa cut-off membrane was used, 1-D SDSPAGE analysis of the retentate (Fig. 3, lane 4) and flow-through (Fig. 3, lane 5) showed that
although high molecular weight proteins were enriched in the retentate, the filtration device
J Proteomics. Author manuscript; available in PMC 2014 June 28.
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also removed proteins with molecular weights below 300 kDa (Fig. 3 boxed area). Filtration
to remove ultra-high MW proteins did prevent proteins from remaining in the well (Fig. 3,
lane 5), but the major problems were that the flow-through was quite diluted and protein
recovery was low, indicating the need for a different approach. Accordingly, we focused on
increasing protein solubility through enzymatic digestion.
2.3. Acid extraction with pepsin digestion
Collagens are among the most abundant ECM components [18] and are highly insoluble in
aqueous reagents. Digestion with pepsin under acidic conditions is one of the most
commonly used methods to solubilize collagen [19,20]. As such, the insoluble pellets from
the ECM-enriched protein homogenates were incubated in acetic acid containing increasing
quantities of pepsin to release pepsin-resistant collagenous polypeptides [21] (strategy 7).
We ran a control lane without pepsin (pellet in acid extraction buffer) in one of our initial
analyses, but the no pepsin control sample was mostly stuck in the well. Pepsin digestion
resulted in improved protein solubility, with minimal protein remaining at the top of the gel
(Fig. 4). However, the sample-to-sample reproducibility was not acceptable.
2.4. Texas 3-Step
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We named the procedure that yielded the best results as the Texas 3-Step protocol, because
it involved resolubilizing the sample in three buffers of increasing strength (strategy 8). LV
samples are initially incubated in a neutral low salt, non-denaturing buffer (0.5 M NaCl, 10
mM Tris base pH 7.5 and 1× PI) for extraction of soluble proteins, including newly
synthesized ECM proteins and degradation products (Step 1). The salts in the buffer
interrupt ionic interactions between proteins, enabling the removal of non-covalently bound
extracellular proteins [22]. The remaining tissue is then decellularized by treatment with
SDS (Step 2). Finally, the insoluble protein fraction that remains is exposed to acid
extraction, deglycosylation, and solubilization (Step 3).
Guanidine HCl (GnHCl) is a widely used protein denaturant that is very effective in
solubilizing the majority of ECM proteins, including large aggregating proteoglycans, small
proteoglycans, cell attachment matrix glycoproteins, and basement membrane components
[3]. GnHCl simultaneously unfolds proteins and interrupts protein–protein interactions.
GnHCl solubilizes ECM components by forming stable hydrogen-bonds to the protein
backbone amides, which results in strong electrostatic repulsions, and destabilizes the ionic,
disulfide-dependent protein conformations [23,24]. Following GnHCl treatment, the heavily
cross-linked interstitial matrix, in particular collagens type I and III, and elastin remain
insoluble [3].

NIH-PA Author Manuscript

ECM enrichment protocols that have stopped at the GnHCl extraction step are not suitable
for proteomic analysis of insoluble ECM components. Mayr’s group reported the use of
deglycosylation to remove glycosaminoglycan (GAG) side chains; this increased the
recovery of proteins in the extracellular environment [3]. Deglycosylation appears to be
critical for solubilizing the remaining ECM proteins, specifically proteoglycans, glycolipids,
and GAGs. Chondroitinase ABC catalyzes the removal of polysaccharides containing 1 →
4-β-D-hexosaminyl and 1 → 3-β-D-glucuronosyl or 1 → 3-α-L-iduronosyl linkages to
disaccharides containing 4-deoxy-β-D-gluc-4-enuronosyl groups [3]. This enzyme also acts
on chondroitin-4-sulfate, chondroitin-6-sulfate, and dermatan sulfate glycosaminoglycan
side chains. Keratanase cleaves internal 1 → 4-β-galactose linkages in unbranched,
repeating poly-N-acetyl-lactosamine and keratan sulfate [25]. Heparinase II cleaves heparin
and heparan sulfate [3,26].

J Proteomics. Author manuscript; available in PMC 2014 June 28.
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Although the deglycosylation step significantly increased protein solubility of the
decellularized LV, a small pellet of insoluble material was still visible. We dissolved this
pellet in dimethyl sulfoxide (DMSO) to further solubilize the remaining ECM components.
Following this step, all ECM proteins were in solution and no visible pellet was observed.
DMSO is a well-known amphipathic solvent and hydrogen bond acceptor. By entering the
aqueous region and interacting with hydrophobic proteins to form a large solvation shell,
DMSO increases the number of sites available for hydrogen bonding and unfolds the protein
[27], making the extended hydrogen-bond networks that stabilize aggregation of the ECM
impossible [28]. By combining different reagents, in a step-by-step manner, we have been
able to isolate and study the majority of the ECM proteins found in the LV. MS analysis of
the insoluble protein fraction (Step 3) identified 157 proteins. This number of proteins was
similar to the number of proteins identified previously with the strategy 4 protocol, when
soluble proteins were excluded. However, only 18% of the proteins identified in the
insoluble fraction of the Texas 3-Step protocol were mitochondrial, whereas when using
Protein Extraction Reagent 4 to solubilize the LV 42% of the proteins identified by MS were
mitochondrial. There were fewer ECM proteins identified in the insoluble fraction compared
to the whole tissue (strategy 4 = 13% vs Texas 3-Step = 11%), since the Texas 3-Step
analysis excluded the soluble ECM proteins present in the soluble fraction. Table 1 shows
the ECM proteins identified by strategies 4 and 8.
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We used immunoblotting to quantify specific ECM proteins identified by MS in each
fraction of the Texas 3-step protocol (Fig. 5) and compared control LV and LV infarct
tissues. Distinctive fragments of collagen were observed in the soluble (Step 1) and
insoluble (Step 3) fractions. Interestingly, cleaved mature collagen (70 kDa) was mainly
observed in the protein fractions of Steps 1 and 2 (Fig. 5b). Fibronectin, an important ECM
protein during LV remodeling post-MI, was predominantly present in the LVI samples and
in Step 1 and 2 fractions. MnSOD, a cellular protein, was present only in the fractions from
Steps 1 and 2, indicating that the Texas 3-Step protocol effectively reduced cellular
components in the insoluble fraction (Step 3). Importantly, protein solubilization was greatly
increased after Step 3, and insoluble proteins were not present in the wells (Fig. 5a boxed
area). With this protocol, we detected increased levels of the 148 kDa soluble procollagen
(Step 1) and reduced levels of the ~300 kDa soluble collagen molecule in LV infarct
compared to control LV tissue. These changes would be masked by the high levels of
collagen fragments in the insoluble fraction (Step 3) if a one-step traditional extraction
protocols were used.

3. Discussion
NIH-PA Author Manuscript

ECM proteins generally have high molecular weights, are difficult to solubilize, are
extensively post-translationally modified, and are usually present in low relative abundance,
hampering comprehensive characterization and quantification [29]. Efficient sample
preparation includes adequate protein solubilization, and avoiding the use of reagents that
will cause downstream interference. We overcame issues with low abundance by enriching
for ECM proteins with a thorough decellularization process. We subsequently focused on
increasing protein solubility. After testing and combining several techniques and extraction
buffers, our final optimized ECM-enrichment protocol, named the Texas 3-Step, separated
the complex samples into three fractions: soluble, cellular, and insoluble proteins, the latter
containing the majority of the ECM components. This method increased protein solubility
considerably, allowed soluble and insoluble proteins to be evaluated separately, and resulted
in the identification of ECM proteins in the insoluble fraction. One possible limitation of this
method is the fact that some soluble ECM proteins may be present in the cellular fraction. In
that case, these ECM proteins would likely be difficult to identify in mass spectrometry
based protocols due to their relatively low abundance compared to the highly abundant
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cellular proteins. Our method is particularly useful for the study of insoluble ECM proteins
but needs to be used cautiously when soluble ECM proteins are to be targeted. In that case,
targeting immunoblotting may be a better approach to take.

4. Methods
All reagents were purchased from Sigma Aldrich (St Louis, MO) unless otherwise stated.
4.1. Animals and surgery
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All animal procedures were conducted according to the “Guide for the Care and Use of
Laboratory Animals” (NIH notice number: NOT-OD-12-020) and were approved by the
Institutional Animal Care and Use Committee at the University of Texas Health Science
Center at San Antonio. Male 4 to 8 month old C57BL6/J wild type (WT) mice were used in
this study [30,31]. Animals were housed at constant temperature (22 ± 2 °C) on a 12 h light/
dark cycle. They were fed standard laboratory mice chow ad libitum and had free access to
tap water. MI was induced by permanent ligation of the left anterior descending coronary
artery, as described previously [32]. At necropsy, mice were anesthetized with 2% isoflurane
in a 100% oxygen mix. The coronary vasculature was flushed with cardioplegic solution (69
mM NaCl, 12 mM NaHCO3, 11 mM glucose, 30 mM 2,3-butanedione monoxime, 10 mM
EGTA, 1 μM nifedipine, 50 mM KCl and 100 U heparin). The left ventricles were separated
from the right ventricles, stained with 1% 2,3,5-triphenyltetrazolium chloride and
photographed for measurement of infarct area. LV infarct (LVI) and remote tissues were
separated and snap frozen in liquid nitrogen.
4.2. Tissue decellularization
The whole left ventricles of unoperated animals were incubated in distilled water with 1×
protease inhibitor cocktail (PI) (cOmplete Mini tablets, Roche) at room temperature for 30
min. The water was decanted and replaced with decellularization buffer. Five
decellularization buffers were tested: buffer # 1, 1% sodium dodecyl sulfate (SDS); buffer #
2, 1% SDS, 20 mM NH4OH; buffer # 3, 1% Triton X-100, 20 mM NH4OH; buffer # 4, 1%
SDS, 1% Triton X-100; buffer # 5, 1% SDS, 1% Triton X-100, 20 mM NH4OH. All
decellularization buffers were prepared in phosphate buffered saline (PBS) with 1× PI.
Samples were left at room temperature in an orbital shaker until tissue was completely
decellularized (three to four days). The decellularization buffer was collected daily and
replaced with fresh decellularization buffer. When tissue looked translucent, samples were
considered decellularized. Tissue was washed three times in distilled water with 1× PI for 5
min, and then left in fresh 1× PI/water overnight to remove all remnants of the
decellularization buffer.
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Two protocols were tested for homogenization of the decellularized samples. 1) Tissue
samples were first homogenized (speed 6, 30 s, Power Gen 1000, Fisher Scientific) in
soluble lysis buffer (0.25 M sucrose, 1 mM EDTA in 50 mM Tris with 1× PI), centrifuged at
14,000 RPM for 1 min, and the insoluble material homogenized (speed 6, 1 min 30 s, Power
Gen 1000, Fisher Scientific) in Protein Extraction Reagent Type 4 (7.0 M urea, 2.0 M
thiourea, 40 mM Trizma base, and 1.0% C7BzO, pH 10.4) and 1× PI. Both the soluble and
the insoluble fractions were stored at −80 °C. 2) Tissue samples were directly homogenized
(speed 6, 1 min 30 s, Power Gen 1000, Fisher Scientific) in Protein Extraction Reagent 4 (15
μL buffer per mg tissue) and stored at −80 °C.
Decellularization with buffer # 1 followed by homogenization with Protein Extraction
Reagent 4 was used to prepare the samples discussed below.

J Proteomics. Author manuscript; available in PMC 2014 June 28.
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Samples were applied to Nanosep centrifugal devices (Pall OD300C33) with a 300 kDa
molecular weight cut-off. Each filter was sanitized with 70% ethanol and rinsed twice with
deionized water before application of 175 μL of the sample. The total spin time for the
samples was 4.5 min.
4.4. Reduction and alkylation
Samples were reduced by adding 1× PI, tributyl phosphine (TBP) to a final dilution of 1:40,
and water to a final volume of 200 μL followed by incubation for 1 h in the dark at room
temperature. Samples were alkylated with iodoacetamide (1:8 relative to the final volume) in
water for 1 h in the dark at room temperature and then centrifuged at slow speed (2000
RPM) for 5 min. The supernatant was transferred to a new tube and proteins were
precipitated with acetone added to a final concentration of 80%, and incubated at room
temperature for 30 min. After centrifugation at 14,000 ×g for 10 min, the supernatant was
discarded. The pellet was allowed to air dry for 5–10 min. The pellet was resuspended in
Protein Extraction Reagent 4, vortexed, and incubated for 30 min at room temperature.
4.5. Acid extraction with pepsin digestion
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Samples were centrifuged at 10,000 RPM, for 10 min at 4 °C. The supernatants were stored
at −80 °C and the pellets used for the acid extraction step. Five hundred microliters of 0.5 M
acetic acid, pH 2.5, was added to the pellet, mixed, and incubated overnight at 4 °C with
agitation. On the next day, samples were centrifuged as described above, and the acid
extraction repeated. After centrifugation at 10,000 RPM, for 10 min at 4 °C, 500 μL of
acetic acid and pepsin (2500 U/mg) was added to the pellet. Three concentrations of pepsin
were tested (0.25, 0.5 and 1 mg/mL), using incubation at 37 °C for either 30 min or 1 h. The
reaction was stopped by addition of ~200 μL of 5 N NaOH to increase the pH to 8.0.
Proteins were visualized by 1-D SDS-PAGE/Coomassie Blue staining.
4.6. Texas 3-Step protocol
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After mincing samples, soluble proteins were extracted by incubation with Step 1 Buffer
(0.5 M NaCl, 10 mM Tris base, pH 7.5, and 1× PI) overnight at 4 °C with agitation for 5 s at
800 RPM every 30 s (Triller Thermoshaker Incubator, PEQLAB Ltd.). After centrifugation
at 14,000 RPM for 1 min, the supernatants (soluble proteins, Step 1) were stored at −80 °C
and the pellets washed twice with Step 2 buffer (1% SDS in PBS and 1× PI). The samples
were then incubated overnight in Step 2 buffer at room temperature, with agitation for 5 s at
800 RPM every 30 s. On the next day, the supernatants were removed and stored at −80 °C
and fresh Step 2 buffer was added to the tissue. This process was repeated until the tissue
was completely decellularized (three to five days). All supernatants from the
decellularization process (containing mainly cellular proteins) were pooled in one tube (Step
2). The decellularized tissue samples were washed twice with deionized water before
homogenization and sonication in Step 3 buffer (4 M GnHCl, 50 mM sodium acetate, pH
5.8 and 1× PI). The samples contain now mainly insoluble proteins; therefore, to increase
solubility samples were maintained for 48 h in Step 3 buffer at room temperature, with
agitation for 5 s at 1000 RPM every 30 s. After centrifugation at 4000 RPM for 25 min at 4
°C, the supernatants were removed and stored at −80 °C (Step 3a) and the pellets washed
with 90% ethanol to remove any residual GnHCl. The pellets were resuspended in
deglycosylation buffer [150 mM NaCl, 50 mM sodium acetate (pH 6.8) and 1× PI] and 0.05
U of each of the following deglycosylation enzymes: chondrotinase ABC from Proteus
vulgaris, endo-β-galactosidase from Bacteroides fragilis, and heparinase II from
Flavobacterium heparinum. The mixture was incubated overnight at 37 °C with agitation. If
a pellet remained after deglycosylation, 20 μL of DMSO was added. These samples were
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pooled with Step 3a to combine all insoluble proteins into one fraction (Step 3). The
insoluble fraction was precipitated with five volumes of cold acetone overnight at 4 °C and
resolubilized in deglycolsylation buffer. This step is essential to remove the GnHCl and
make samples amenable for mass spectrometry analysis. The total protein in each fraction
from Steps 1, 2 and 3 was determined using the Quick Start Bradford Protein Assay (BioRad). Proteins in each fraction were separated by 1-D SDS-PAGE and visualized by staining
with Coomassie Blue.
4.7. Immunoblotting
An aliquot of each sample (1 or 5 μg protein) was loaded onto a 4–12% Bis–Tris gel and
separated by electrophoresis. Proteins were transferred to a nitrocellulose membrane which
was hybridized overnight at 4 °C with primary antibodies against the following: collagen
type I (#CL50141AP-1, Cedarlane), fibronectin (#F6140, Sigma), GAPDH (#ab9485,
Abcam), and MnSOD (#SOD-111, Assay Designs).
4.8. Mass spectrometry
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Proteins (12.75 μg) were separated in a 4–12% Bis–Tris gel. The gel region containing
visually detectable proteins was excised into three slices. Each slice was separately
destained and dehydrated and the proteins digested in situ with trypsin (Promega). The
digests were analyzed by capillary HPLC–electrospray ionization tandem mass spectrometry
(HPLC–ESI–MS/MS) on a Thermo Fisher LTQ Orbitrap Velos mass spectrometer fitted
with a New Objective Digital PicoView 550 NanoESI source. Online HPLC separation of
the digests was accomplished with an Eksigent/AB Sciex NanoLC-Ultra 2-D HPLC system:
column, PicoFrit™ (New Objective; 75 μm i.d.) packed to 15 cm with C18 adsorbent
(Vydac; 218MS 5 μm, 300 Å). Precursor ions were acquired in the Orbitrap in profile mode
at 60,000 resolution (m/z 400); data-dependent collision-induced dissociation (CID) spectra
of the six most intense ions in the precursor scan above a set threshold were acquired
sequentially in the linear trap at the same time as the precursor ion scan. Mascot (version
2.3.02; Matrix Science) was used to search the CID spectra against a combination of the
mouse subset of the NCBInr database [3/ 12/2011 version; Mus. (145,083 sequences)] and a
database of common contaminants (179 sequences). Methionine oxidation was considered as
a variable modification; trypsin was specified as the proteolytic enzyme, with one missed
cleavage allowed. The mass tolerances used for the searches were: precursor, 20 ppm;
product ion, 0.8 Da. [The majority of identified peptides were detected with a mass error of
≤5 ppm]. The Mascot data files were combined in Scaffold (Proteome Software; version 3)
for a subset search of the CID spectra using X! Tandem, cross correlation of the X! Tandem,
Mascot results, determination of protein, and peptide identity probabilities. The thresholds
for acceptance of peptide and protein assignments in Scaffold were 95% and 99.9%,
respectively, and minimum of two unique peptides.
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Fig. 1.
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Description of the evolution of strategies developed for the enrichment of cardiac ECM
proteins to facilitate analysis by mass spectrometry.
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Fig. 2.

a. Image of decellularized and untreated mouse left ventricle (LV); b. proteins in
decellularized LV samples from young (4 to 8 month old) wild type mice (n = 10 biological
replicas) were visualized in a 1-D SDS-PAGE gel (strategy 4). Lane 1 is the molecular
weight (MW) marker. Poor sample solubility caused insoluble proteins to stay trapped in the
wells (boxed region), resulting in decreased electrophoretic mobility; c. immunoblots (5 μg
total protein) of fibronectin, MnSOD, and GAPDH in soluble (lysis buffer) and insoluble
(Protein Extraction Reagent 4) young LV protein extracts. Decellularization buffer # 1 (1%
SDS): lanes 1 and 4. Decellularization buffer # 2 (1% SDS, 20 mM NH4OH): lanes 2 and 5.
Untreated LV (lanes 3 and 6) and cellular extract (lane 7) were used as controls. Lane
descriptions apply to Fig. 2c.
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Fig. 3.

Two treatments were used to increase sample solubility and enhance protein resolution by
electrophoresis: protein reduction/alkylation and filtration of high molecular weight
proteins. The Coomassie Blue stained gel shows proteins in decellularized LV samples
before and after treatments. Lane 1: molecular weight (MW) marker; lane 2: control
untreated sample; lane 3: LV sample after reduction/ alkylation; lane 4: >300 kDa protein
fraction of a decellularized LV sample after membrane filtration; lane 5: <300 kDa protein
fraction of decellularized LV sample (same sample as in lane 4). Reduction and alkylation of
the decellularized LV increased sample solubility but proteins were smeared, suggesting
over-denaturation. Filtration to remove ultra-high MW proteins did prevent proteins from
remaining in the well (<300 kDa, lane 5), but as observed in lane 4 the filtration device also
removed proteins with molecular weights below 300 kDa (boxed area).
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Fig. 4.

Coomassie Blue stained gel of decellularized LV extracts after acid extraction in
conjunction with pepsin digestion. Pepsin treatment improved protein resolution on the gel.
The same LV extract was treated with increasing quantities of pepsin for 30 min or 1 h.
MW, molecular weight marker.
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Fig. 5.

Protein fractions resulting from the Texas 3-Step protocol. a. Coomassie Blue stained gel (1
μg total protein per lane). No proteins were observed trapped in the wells, which shows an
improved protein resolution compared to the previous tested strategies (boxed area).
Immunoblots: b. collagen type I; c. fibronectin; and d) MnSOD; and d. fibronectin,
densitometry analysis was normalized to total protein, *p < 0.05 versus respective control.
By using a differential solubility-based, protein fractionation strategy, we unmasked protein
differences (arrows) that otherwise would not be noticeable by a 1-fraction method. Step 1:
soluble proteins; Step 2: cellular proteins; Step 3: insoluble proteins. MW: molecular
weight; Ctr: LV control tissue from unoperated mice (n = 4); LVI: LV infarcted tissue 5
days post-MI (n = 4).
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ECM proteins identified in the LV infarcted tissue of WT mice, 5 days post-MI, by two methods: ECMenrichment by SDS decellularization and solubilization with Protein Extraction Reagent 4 (strategy 4), and
Texas 3-Step (Step 3, insoluble fraction only). Proteins identified by mass spectrometry are listed
alphabetically.
ECM identified proteins
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Strategy 4

Texas 3-Step (insoluble fraction)

Collagen I alpha-1

138

X

X

Collagen I alpha-2

130

X

X

Collagen III alpha-1

139

X

X

Collagen IV alpha-1

161

Collagen IV alpha-2

167

X

X

Collagen V alpha-1

184

X

X

Collagen VI alpha-1

108

X

X

Collagen VI alpha-2

110

X

X

Collagen VI alpha-3

352

X

X

Emilin 1

108

X

X

Fibrillin-1

312

X

X

Fibronectin

272

X

X

Fibulin-2

132

X

Laminin alpha-2

343

X

Laminin alpha-5

404

X

Laminin beta-1

197

X

Laminin beta-2

196

X

Laminin gamma-1

177

X

Nidogen-1

137

X

Periostin

93

X

X

Perlecan

398

X

X

Tenascin C

222
20

17

Total

Molecular weight (kDa)

X

X

X

X
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